Cover Image
市場調查報告書

體外受精 (IVF) 的全球市場 - 各國 (美國、中國、加拿大、印度、日本、英國) 市場、企業簡介、佔有率、趨勢、分析、規模、機會、分類及2015年∼2021年的預測

Global In Vitro Fertilization (IVF) Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 345634
出版日期 內容資訊 英文 135 Pages
商品交期: 請詢問到貨日
價格
Back to Top
體外受精 (IVF) 的全球市場 - 各國 (美國、中國、加拿大、印度、日本、英國) 市場、企業簡介、佔有率、趨勢、分析、規模、機會、分類及2015年∼2021年的預測 Global In Vitro Fertilization (IVF) Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022
出版日期: 2016年01月22日 內容資訊: 英文 135 Pages
簡介

不孕是全世界的問題,每6組伴侶有1組,20∼44歲的女性中有10%有不孕煩惱。一般認為全球體外受精 (IVF) 及不孕治療市場2014∼2021年將以6.1%的年複合成長率擴大。

本報告提供全球體外受精 (IVF)、男性及女性的不孕治療市場相關調查、市場趨勢以及到2012年的收益預測與成長率、產業分析、競爭趨勢、各地區趨勢,及進入的主要企業簡介彙整。

第1章 目錄

第2章 市場概要

  • 藥物市場佔有率和荷爾蒙療法
  • 主要的購買標準
  • 主要調查結果

第3章 男性及女性的不孕

  • 原因
    • 男性的不孕原因
    • 女性的不孕原因
  • 不孕治療的倫理問題

第4章 市場決策因素

  • 推動市場的要素
    • 不孕的增加
    • 不孕治療旅遊觀光事業
    • 擔負不孕治療旅遊觀光事業責任的代理孕母
    • 治療成功率的上升
    • 消費者接收捐贈者卵子的增加
  • 阻礙市場的要素
    • 高價的治療
    • 法律問題
  • 市場機會
    • 對體外受精的低成本設備和藥物的全球性要求
    • 對私人股權投資者而言體外受精是富有魅力的投資處
    • 生殖旅遊觀光事業
  • 市場課題
    • 新興市場上費用障礙
    • 男性的不孕治療的意識低
    • 多胎及出生異常

第5章 市場分類

  • 男性的不孕市場
  • 女性的不孕市場

第6章 各地區市場分類

  • 北美
  • 亞洲
  • 歐洲

第7章 企業分析

  • Andrology Solutions
  • Auxilium Pharmaceuticals
  • Auxogyn
  • Ferring Pharmaceuticals
  • Genea
  • Halotech DNA
  • Irvine Scientific
  • Merck Serono
  • Origio
  • Ovascience
  • Vitrolife AB

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HME-661114

Infertility is one of the major concerns in the world. One out of six couples in the world suffers from some form of infertility. About 10% women aged 20-44 suffer from infertility. There are various causes for infertility which include physiological (20-30% cases), some cases include genetically induced disorders whereas sometimes it may be self induced as in case of contraceptive surgeries. The market is driven by rising awareness amongst couples, a strong and developed health structure in developing nations, low cost treatment options available, and rise in the new methods like in vitro activation and surrogacy.

The testing and treatment market is growing at a faster rate in males than females. The earlier social taboos among men regarding male fertility have been declining, leading to increase in the male infertility testing and treatment market.

The cost of fertility treatment varies vastly from country to country leading to a rise in medial tourism in relationship with fertility treatments Israel is one of the leading countries with high quality treatments for infertility. The success rate of infertility treatment in Israel is around 46% which in one of the best globally

The companies profile in this report include

  • 1. Merck Sereno
  • 2. Origio
  • 3. Vitrolife AB
  • 4. Axilium Pharma
  • 5. Andology Solutions
  • 6. Auxillum Pharmaceuticals
  • 7. Auxogyn
  • 8. Ferring Pharmaceuticals
  • 9. Genea
  • 10. Helotech DNA
  • 11. Ovascience

This Occams Research Report covers

  • 1. Historical data
  • 2. Revenue forecasts, growth rates and CAGR upto 2022
  • 3. Industry Analysis
  • 4. Competitive Analysis
  • 5. Key geographic growth data
  • 6. Deep profiles top competitive companies

Table of Contents

Chap 1. Executive Summary

Chap 2. Market overview

  • 2.1. Market Share for Drug & Hormone Therapy
  • 2.2. Key buying criteria
    • 2.2.1. Treatment options
    • 2.2.2. Quality of medical procedures
    • 2.2.3. Price of treatments
    • 2.2.4. Shift towards medical tourism
    • 2.2.5. Reimbursement
  • 2.3. Key Findings
    • 2.3.1. highest growth in Male infertility treatment segment
    • 2.3.2. Fertility tourism- The biggest and the growing trend
    • 2.3.3. Upper middle income group is the key target
    • 2.3.4. Regulatory environment key market enabler
    • 2.3.5. Surrogacy preferred for failures in IVF treatments
    • 2.3.6. Technological advancement enhancing success rates of fertility treatments

Chap 3. Male and Female Infertility

  • 3.1. Causes
    • 3.1.1. Causes of male infertility
      • 3.1.1.1. Medical reasons
      • 3.1.1.2. Environmental factors
      • 3.1.1.3. Lifestyle issues
    • 3.1.2. Causes of female infertility
      • 3.1.2.1. Ovulatory disorders
      • 3.1.2.2. Poor functioning or damage to fallopian tube and other issues
  • 3.2. Ethical issues in infertility treatment

Chap 4. Market Determinants

  • 4.1. Market Drivers
    • 4.1.1. Rise in infertility
    • 4.1.2. Fertility Tourism
    • 4.1.3. Surrogacy also responsible for fertility tourism
    • 4.1.4. Technological advancement in healthcare domain
    • 4.1.5. Increase in success rate of treatments
    • 4.1.6. Increasing acceptance of donor eggs by consumers
  • 4.2. Market Restraints
    • 4.2.1. Expensive procedure
    • 4.2.2. Legal issues
  • 4.3. Market Opportunities
    • 4.3.1. Global requirement for low cost instruments and drugs in IVF
    • 4.3.2. IVF an attractive sector for investment for private equity investors
    • 4.3.3. Reproductive tourism
  • 4.4. Market Challenges
    • 4.4.1. Cost barrier for locals in emerging economies
    • 4.4.2. Low acceptance of infertility treatment amongst men
    • 4.4.3. Multiple births and birth defects

Chap 5. Market Segmentation

  • 5.1. Male Infertility Market
    • 5.1.1. Male Infertility tests
      • 5.1.1.1. Semen analysis techniques
        • 5.1.1.1.1. CASA provides more accurate results in lesser time
      • 5.1.1.2. DNA fragmentation
        • 5.1.1.2.1. Importance of sperm DNA fragmentation
        • 5.1.1.2.2. When the test is conducted
        • 5.1.1.2.3. Causes of Sperm DNA fragmentation
      • 5.1.1.3. Oxidative Stress Analysis
      • 5.1.1.4. Testicular Biopsy
      • 5.1.1.5. Azoospermia is the reason in 15 percent infertile males
      • 5.1.1.6. Risks in testicular biopsy
      • 5.1.1.7. CNB and FNA Mapping is an emerging trend
    • 5.1.2. Male infertility treatment types
      • 5.1.2.1. Surgery
        • 5.1.2.1.1. Vasovasectomy and Vasoepididymostomy (Vasectomy reversal)
        • 5.1.2.1.2. Sperm Retrieval Treatment
          • 5.1.2.1.2.1. Microsurgical Sperm Aspiration (MESA)
          • 5.1.2.1.2.2. Testicular Sperm Extraction (TESE)
        • 5.1.2.1.3. Varicocele repairs
        • 5.1.2.1.4. Drug & Hormone Therapy
        • 5.1.2.1.5. Assisted Reproductive Techniques (ART)
          • 5.1.2.1.5.1. Intrauterine insemination (IUI)
          • 5.1.2.1.5.2. In vitro fertilization (IVF)
          • 5.1.2.1.5.3. Intra cytoplasmic sperm injection (ICSI)
  • 5.2. Female infertility
    • 5.2.1. Female infertility test
      • 5.2.1.1. Ovulation Testing
      • 5.2.1.2. Hysterosalpingography
      • 5.2.1.3. Laparoscopy
      • 5.2.1.4. Ovarian reserve testing
      • 5.2.1.5. Genetic Testing
    • 5.2.2. Female infertility treatment types
      • 5.2.2.1. In vitro fertilization
      • 5.2.2.2. Intrauterine insemination (IUI)
      • 5.2.2.3. Drug and hormone therapies

Chap 6. IVF & Infertility market geography wise

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Canada
      • 6.1.2.1. Regulation for IVF in Canada
  • 6.2. Asia
    • 6.2.1. China
    • 6.2.2. India
      • 6.2.2.1. Growing fertility tourism in India
      • 6.2.2.2. Need for a regulatory framework
    • 6.2.3. Japan
      • 6.2.3.1. Fertility Regulations in Japan
    • 6.2.4. South Korea
    • 6.2.5. Thailand
    • 6.3. Europe
    • 6.3.1. Italy
    • 6.3.2. France
      • 6.3.2.1. Regulations in France
      • 6.3.2.2. Low cost treatment with social security cover in France
    • 6.3.3. Germany
      • 6.3.3.1. Coverage Policy
      • 6.3.3.2. Regulations
    • 6.3.4. Spain
      • 6.3.4.1. Regulations in Spain
    • 6.3.5. Russia
      • 6.3.5.1. Regulations

Chap 7. Company Profiling

  • 7.1. Andrology Solutions
    • 7.1.1. Overview
    • 7.1.2. Product Portfolio
    • 7.1.3. SCOT Analysis
  • 7.2. Auxilium Pharmaceuticals
    • 7.2.1. Overview
    • 7.2.2. Product Portfolio
    • 7.2.3. Revenue Analysis
    • 7.2.4. Strategic Moves
    • 7.2.5. SCOT Analysis
  • 7.3. Auxogyn
    • 7.3.1. Overview
    • 7.3.2. Products
    • 7.3.3. Strategic Moves
    • 7.3.4. SCOT Analysis
  • 7.4. Ferring Pharmaceuticals
    • 7.4.1. Overview
    • 7.4.2. Product Portfolio
    • 7.4.3. Strategic Moves
    • 7.4.4. SCOT Analysis
  • 7.5. Genea
    • 7.5.1. Overview
    • 7.5.2. Product Portfolio
    • 7.5.3. Strategic Moves
    • 7.5.4. SCOT Analysis
  • 7.6. Halotech DNA
    • 7.6.1. Overview
    • 7.6.2. Product Portfolio
    • 7.6.3. Strategic Moves
    • 7.6.4. SCOT Analysis
  • 7.7. Irvine Scientific
    • 7.7.1. Overview
    • 7.7.2. Product Portfolio
    • 7.7.3. Strategic Moves
    • 7.7.4. SCOT Analysis
  • 7.8. Merck Serono
    • 7.8.1. Overview
    • 7.8.2. Product Portfolio
    • 7.8.3. Revenue Analysis
    • 7.8.4. Strategic Moves
    • 7.8.5. SCOT Analysis
  • 7.9. Origio
    • 7.9.1. Overview
    • 7.9.2. Product Portfolio
    • 7.9.3. Strategic Moves
    • 7.9.4. SCOT Analysis
  • 7.10. Ovascience
    • 7.10.1. Overview
    • 7.10.2. Product Portfolio
    • 7.10.3. Strategic Moves
    • 7.10.4. SCOT Analysis
  • 7.11. Vitrolife AB
    • 7.11.1. Overview
    • 7.11.2. Strategic Moves
    • 7.11.3. SCOT Analysis
Back to Top